Literature DB >> 33597150

Functional Characteristics and Phenotypic Plasticity of CD57+PD1- CD4 T Cells and Their Relationship with Transplant Immunosuppression.

Brian I Shaw1, Jaclyn R Espinosa2, Linda Stempora2, Allison Miller2, Bartley Adams2, Allan D Kirk2.   

Abstract

Costimulation blockade (CoB)-based immunosuppression offers the promise of improved transplantation outcomes with reduced drug toxicity. However, it is hampered by early acute rejections, mediated at least in part by differentiated, CoB-resistant T cells, such as CD57+PD1- CD4 T cells. In this study, we characterize these cells pretransplant, determine their fate posttransplant, and examine their proliferative capacity in vitro in humans. Our studies show that CD57+PD1- CD4 T cells are correlated with increasing age and CMV infection pretransplant, and persist for up to 1 y posttransplant. These cells are replication incompetent alone but proliferated in the presence of unsorted PBMCs in a contact-independent manner. When stimulated, cells sorted by CD57/PD1 status upregulate markers of activation with proliferation. Up to 85% of CD57+PD1- cells change expression of CD57/PD1 with stimulation, typically, upregulating PD1 and downregulating CD57. PD1 upregulation is accentuated in the presence of rapamycin but prevented by tacrolimus. These data support a general theory of CoB-resistant cells as Ag-experienced, costimulation-independent cells and suggest a mechanism for the synergy of belatacept and rapamycin, with increased expression of the activation marker PD1 potentiating exhaustion of CoB-resistant cells.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Year:  2021        PMID: 33597150      PMCID: PMC7987798          DOI: 10.4049/jimmunol.2000736

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

Authors:  A D Wells; X C Li; Y Li; M C Walsh; X X Zheng; Z Wu; G Nuñez; A Tang; M Sayegh; W W Hancock; T B Strom; L A Turka
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Increased Pretransplant Frequency of CD28+ CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients.

Authors:  M Cortes-Cerisuelo; S J Laurie; D V Mathews; P D Winterberg; C P Larsen; A B Adams; M L Ford
Journal:  Am J Transplant       Date:  2017-06-30       Impact factor: 8.086

3.  IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection.

Authors:  He Xu; Victoria A Bendersky; Todd V Brennan; Jaclyn R Espinosa; Allan D Kirk
Journal:  Am J Transplant       Date:  2017-12-12       Impact factor: 8.086

4.  Costimulation blockade with belatacept in renal transplantation.

Authors:  Flavio Vincenti; Christian Larsen; Antoine Durrbach; Thomas Wekerle; Björn Nashan; Gilles Blancho; Philippe Lang; Josep Grinyo; Philip F Halloran; Kim Solez; David Hagerty; Elliott Levy; Wenjiong Zhou; Kannan Natarajan; Bernard Charpentier
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

Review 6.  CD28 negative T cells: is their loss our gain?

Authors:  D Mou; J Espinosa; D J Lo; A D Kirk
Journal:  Am J Transplant       Date:  2014-10-16       Impact factor: 8.086

7.  An economic assessment of contemporary kidney transplant practice.

Authors:  David A Axelrod; Mark A Schnitzler; Huiling Xiao; William Irish; Elizabeth Tuttle-Newhall; Su-Hsin Chang; Bertram L Kasiske; Tarek Alhamad; Krista L Lentine
Journal:  Am J Transplant       Date:  2018-03-31       Impact factor: 8.086

8.  CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection.

Authors:  J Espinosa; F Herr; G Tharp; S Bosinger; M Song; A B Farris; R George; J Cheeseman; L Stempora; R Townsend; A Durrbach; A D Kirk
Journal:  Am J Transplant       Date:  2016-01-14       Impact factor: 8.086

9.  Belatacept and Long-Term Outcomes in Kidney Transplantation.

Authors:  Flavio Vincenti; Lionel Rostaing; Joseph Grinyo; Kim Rice; Steven Steinberg; Luis Gaite; Marie-Christine Moal; Guillermo A Mondragon-Ramirez; Jatin Kothari; Martin S Polinsky; Herwig-Ulf Meier-Kriesche; Stephane Munier; Christian P Larsen
Journal:  N Engl J Med       Date:  2016-01-28       Impact factor: 91.245

10.  Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.

Authors:  Vincent Hurez; Vinh Dao; Aijie Liu; Srilakshmi Pandeswara; Jonathan Gelfond; Lishi Sun; Molly Bergman; Carlos J Orihuela; Veronica Galvan; Álvaro Padrón; Justin Drerup; Yang Liu; Paul Hasty; Zelton Dave Sharp; Tyler J Curiel
Journal:  Aging Cell       Date:  2015-08-28       Impact factor: 9.304

View more
  2 in total

Review 1.  Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.

Authors:  Imran J Anwar; Isabel F DeLaura; Qimeng Gao; Joseph Ladowski; Annette M Jackson; Jean Kwun; Stuart J Knechtle
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 2.  Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection.

Authors:  Marcos Iglesias; Daniel C Brennan; Christian P Larsen; Giorgio Raimondi
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.